Best Peptide for Hair Growth
GHK-Cu, TB-500, Ipamorelin & Thymosin Beta-4 — Ranked for Hair Regrowth (2026)
Hair growth peptides target follicle stimulation, scalp microcirculation, keratinocyte migration, and DHT-independent growth signalling. GHK-Cu is the most studied peptide for follicle activation and has direct evidence for follicle enlargement. TB-500 (Thymosin Beta-4) promotes follicular stem cell mobilisation from the hair bulge. Ipamorelin stimulates growth hormone, which drives scalp IGF-1 production critical for follicular anabolism. Track any hair growth protocol in Shotlee.
Top Hair Growth Peptides — Ranked by Evidence
| Peptide | Hair Growth Mechanism | Best Evidence | Application | Evidence Level |
|---|---|---|---|---|
| GHK-Cu | Wnt pathway activation, follicle IGF-1, anti-5-alpha-reductase, fibronectin | Cell culture: follicle enlargement; animal hair regrowth; human observational | Topical serum (1–5%) or SC injection | ⭐⭐⭐⭐Best |
| TB-500 (Thymosin Beta-4) | Follicular bulge stem cell mobilisation, keratinocyte migration, anti-inflammatory | NIH study: stem cell mobilisation for hair regeneration | SC injection 2–5 mg 2x/week | ⭐⭐⭐ |
| Ipamorelin / GH secretagogues | GH pulse → scalp IGF-1 → follicular anabolism, anti-catabolism | GH deficiency hair loss reversal; scalp IGF-1 studies | SC injection before bed | ⭐⭐⭐ |
| Epithalon | Telomere maintenance in follicular stem cells, anti-aging of scalp biology | Telomere lengthening data; follicular stem cell longevity theory | SC injection or intranasal, cycled | ⭐⭐ |
| BPC-157 | VEGF angiogenesis → improved scalp microcirculation | Animal scalp angiogenesis data; indirect follicle vascular support | SC injection or topical | ⭐⭐ |
| RU-58841 (non-peptide) | Androgen receptor antagonist in scalp (blocks DHT locally) | Animal androgenic alopecia reversal; widely used off-label | Topical scalp solution | ⭐⭐⭐ |
Top Hair Growth Picks Explained
GHK-Cu — The Most Studied Hair Peptide
GHK-Cu stimulates hair follicle growth through several converging mechanisms: upregulates IGF-1 expression within the follicle itself (a critical local growth signal); enlarges follicle size from miniaturised to full-size (the hallmark of androgenic alopecia reversal); increases fibronectin in the dermal papilla; and has anti-5-alpha-reductase properties reducing local DHT conversion. Applied topically (1–5% scalp serum) or systemically via SC injection. Arguably the most mechanistically complete hair growth peptide.
TB-500 (Thymosin Beta-4) — Stem Cell Mobilisation
NIH researcher Lorna Horne demonstrated that Thymosin Beta-4 promotes mobilisation of hair follicle stem cells from the bulge region — the reservoir that regenerates each hair shaft cycle. By activating these dormant stem cells, TB-500 can restart sleeping follicles and accelerate the hair growth cycle. Also reduces follicular inflammation — a key driver of alopecia areata. Used as SC injection (2.5–5 mg 2x/week) alongside topical GHK-Cu for a two-pronged hair restoration approach.
Ipamorelin — GH-Axis Hair Support
Growth hormone is critical for scalp IGF-1 production and follicular anabolism. GH deficiency consistently causes hair loss and thinning. Ipamorelin stimulates clean GH pulses without cortisol or prolactin elevation — the safest GHRP for ongoing use. Elevated scalp IGF-1 from GH pulses supports follicle growth phase duration and hair shaft diameter. Most relevant for hair loss associated with GH decline, post-menopausal hair loss, or slow follicular regrowth after previous hair loss treatment.
Epithalon — Scalp Cellular Longevity
Follicular stem cells in the hair bulge have finite replicative capacity limited by telomere shortening. As telomeres shorten with age, stem cells lose their ability to regenerate follicles — a key mechanism of age-related hair thinning. Epithalon's telomerase-activating mechanism extends the replicative capacity of follicular stem cells. Used as cycled SC injection courses (10 days, 1–2x per year) as part of a comprehensive anti-aging hair protocol. Effects are cumulative over multiple cycles.
BPC-157 — Scalp Microcirculation
Miniaturised follicles in androgenic alopecia have reduced vascular support compared to healthy follicles. BPC-157's potent VEGF upregulation drives new capillary formation in the scalp dermis, improving nutrient delivery to follicles. Also reduces scalp inflammation that damages follicular stem cell niches. Used as SC injection or in topical scalp delivery systems. Best as a vascular support complement to GHK-Cu and Thymosin Beta-4 in comprehensive protocols.
How to Choose the Right Hair Growth Peptide
For most androgenic alopecia (male or female pattern hair loss), the most evidence-aligned peptide protocol is topical GHK-Cu serum (1–5% concentration, applied daily) as the foundation, with systemic TB-500 (2.5 mg SC 2x/week) to mobilise follicular stem cells. This two-pronged approach addresses both the local follicular growth signal (GHK-Cu) and the stem cell regeneration cycle (TB-500).
If scalp circulation is compromised (evidenced by poor scalp vascularity, cold scalp, or diffuse thinning rather than pattern loss), add BPC-157 SC injection to support angiogenesis. If the hair loss has a clear GH-axis component (associated with fatigue, body composition changes, or GH decline), Ipamorelin before bed addresses the systemic hormonal environment for hair growth.
Peptides work best when combined with established hair loss treatments. RU-58841 topical addresses the DHT-mediated follicle miniaturisation that peptides alone cannot fully reverse. Track your protocol in Shotlee — photograph the thinning area monthly under consistent lighting, record hair shedding counts on washing days, and document new hair growth. Expect 3–6 months for visible results.
How to Track Your Hair Growth Protocol in Shotlee
Frequently Asked Questions
GHK-Cu has the strongest mechanistic evidence for hair regrowth among peptides: cell culture studies show follicle enlargement, increased follicular IGF-1, and dermal papilla cell proliferation. Animal studies demonstrate visible hair regrowth at topical application sites. Human observational and case data show promising results for early-to-moderate androgenic alopecia. No large Phase 3 RCTs exist specifically for hair loss, but the mechanistic and observational evidence is compelling enough to support clinical use.
TB-500 (Thymosin Beta-4) has specific mechanistic evidence for hair loss from NIH research by Lorna Horne showing it promotes follicular stem cell mobilisation from the bulge region. It also reduces follicular inflammation contributing to alopecia areata. Typically used as 2.5 mg SC 2x/week combined with topical GHK-Cu. Results take 2–4 months as the hair growth cycle progresses.
Hair growth peptides require patience — the hair cycle (anagen, catagen, telogen) takes months to complete. Typical timeline: weeks 1–4, shedding reduction; weeks 4–8, new fine hairs visible; weeks 8–16, density improvement in treated areas. Track weekly shedding counts and monthly photos in Shotlee to see progress before it is obvious in the mirror.
Peptides address DHT-mediated hair loss incompletely. GHK-Cu has anti-5-alpha-reductase properties that reduce local DHT conversion, but this effect is weaker than dedicated DHT blockers (finasteride, dutasteride). For androgenic alopecia, peptides work best when combined with a DHT-blocking agent targeting the root cause alongside peptide-driven follicular stimulation.
The most evidence-aligned hair growth peptide stack: topical GHK-Cu serum (1–5%, daily) + TB-500 SC injection (2.5 mg, 2x/week) + BPC-157 SC injection (250 mcg/day if scalp circulation is poor) + Ipamorelin before bed (if GH-axis support is desired). Track all compounds and hair metrics in Shotlee.
Track Your Hair Growth Protocol in Shotlee
Log every dose, weekly shedding count, and monthly progress photo. Hair growth takes months — data tracking reveals the trend before you can see it.